Pacific Biosciences of California  

(Public, NASDAQ:PACB)   Watch this stock  
Find more results for Michael A. Corcoran�
5.42
-0.09 (-1.54%)
Mar 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.38 - 5.58
52 week 3.87 - 8.78
Open 5.46
Vol / Avg. 618,635.00/615,082.00
Mkt cap 410.21M
P/E     -
Div/yield     -
EPS -0.94
Shares 74.52M
Beta 2.47
Inst. own 64%
May 12, 2015
Pacific Biosciences of California Inc at Bank of America Merrill Lynch Health Care Conference Add to calendar
Apr 28, 2015
Q1 2015 Pacific Biosciences of California Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 2, 2015
Pacific Biosciences of California Inc at Cowen Health Care Conference
Feb 3, 2015
Q4 2014 Pacific Biosciences of California Inc Earnings Call - Webcast
Feb 3, 2015
Q4 2014 Pacific Biosciences of California Inc Earnings Release
Jan 14, 2015
Pacific Biosciences of California Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -112.25% -109.19%
Operating margin -105.86% -103.73%
EBITD margin - -96.76%
Return on average assets -61.84% -50.75%
Return on average equity -140.96% -106.60%
Employees 344 -
CDP Score - -

Address

1380 Willow Rd.
MENLO PARK, CA 94025
United States - Map
+1-650-5218000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pacific Biosciences of California, Inc. is engaged in the developing, manufacturing and marketing tools for biological research. The Company has developed a technology to study the synthesis, composition, structure and regulation of DNA by combining advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics. Its SMRT technology enables real-time analysis of biomolecules with single molecule resolution, which has the potential to transform its understanding of biological systems by providing a window into these systems that has not previously been open for scientific study. The Company has developed PacBio RS II, which uses its SMRT technology. It consists of an instrument platform that uses its consumables including its SMRT Cell. The PacBio RS II is an instrument that conducts, monitors, and analyzes single molecule biochemical reactions in real time.

Officers and directors

Michael W. Hunkapiller Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Susan K. Barnes Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Kevin P. Corcoran Senior Vice President - Market Development
Age: 55
Bio & Compensation  - Reuters
Michael Phillips Senior Vice President - Research and Development
Age: 63
Bio & Compensation  - Reuters
William Ericson Lead Independent Director
Age: 55
Bio & Compensation  - Reuters
Kathy P. Ordonez Director
Age: 63
Bio & Compensation  - Reuters
David Botstein Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Brook H. Byers Ph.D Independent Director
Age: 68
Bio & Compensation  - Reuters
Randy Livingston Independent Director
Age: 60
Bio & Compensation  - Reuters